ReviewTheranostics2026
Micro/nanorobotics for sepsis diagnosis and therapy: a frontier in precision medicine.
Review in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis is a serious, life-threatening widespread inflammatory response in the body to infection that can result in multiple organ damage and has a relatively high death rate. Traditional antibiotics and supportive treatments have certain deficiencies, such as poor drug accumulation at the site of infection, delayed identification of pathogens, and an inability to precisely regulate the host immune response. New developments in micro- and nanorobotics have provided new paths for sepsis diagnosis and treatment by means of active motion, intelligent sensing and targeted intervention. Biohybrid microrobots containing DNA nanodevices or enzyme sensors can be used for diagnosis to rapidly detect bacterial pathogens, endotoxins and other markers such as procalcitonin. Motivated micro-robots can overcome the biofilm barrier to deliver drugs and increase the local concentration of antibiotics to inhibit bacterial toxins. Functionalised nanobots of cell membrane or enzyme types can target cytokines, reactive oxygen species and circulating mitochondrial DNA to suppress inflammation and organ damage. The above-mentioned multi-functional platforms have combined pathogen clearance, immune modulation and tissue repair into one treatment. Although the above are promising, there are still some problems in biosafety, propulsion efficiency under complex physiological conditions, large-scale production, and the development of clinically relevant animal models. Future work will focus on building intelligent, biocompatible systems capable of autonomous navigation and adaptation to sepsis. Micro- and nanorobots are generally considered to be a new type of devices for treating sepsis that can achieve targeted and personalised therapy through intelligence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.